A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type - A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type (FUTURE1101)

Fukuoka Tumor Research(FUTURE)0 个研究点目标入组 0 人开始时间: 2011年3月9日最近更新: 2023年10月17日

试验速览

•1)Patients with severe complications,(severe cardiovascular disease,severe heart disease,heart failure,liver failure,renal failure or uncontrollable diabetes mellitus) 2)Patients with active infection 3)Patients with severe interstitial pneumonitis or pulmonary fibrosis 4)Patients with active double cancer 5)Patients with paralytic ileus, bowel obstruction 6)Patients with uncontrollable ascites and pleural effusion 7)Patients with diarrhea 8)Patients with the past history of severe allergic reactions 9)Patient with regular use of furucytocin or fenytoin,warfarin 10)psychiatric patients 11)pregnant or nursing patient or with intent to bear baby 12)Patients with the past history of treatment of S-1 and CPT-11 and Panitumumab, Cetuximab 13)Patients with regular use of steroids(oral or intravenous) 14)Patients with brain metastasis 15)Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial

发起方

Fukuoka Tumor Research(FUTURE)